Loading…
Trial eligibility change
| eligibility_criteria | Inclusion Criteria: * Age ≥21 years at the time of enrollment * Confirmed diagnosis of ulcerative colitis (UC) or Crohn's disease (CD) * Eligible for treatment with biologic therapy for IBD, defined as failure of prior conventional therapy and/or prior biologic therapy (excluding IL-23p19 antagonists) * No prior exposure to mirikizumab and no contraindications to mirikizumab * Ability to provide informed consent * Willingness to comply with study procedures and follow-up requirements Exclusion Criteria: * Prior exposure to IL-23p19 antagonists (e.g., mirikizumab, risankizumab, guselkumab) * Prior exposure to small molecule targeted therapies for IBD (e.g., JAK inhibitors or S1P receptor modulators) * Participation in an interventional clinical trial within 90 days prior to enrollment * History of extensive colorectal resection, including: * Total proctocolectomy (for UC), or * Surgical removal of two or more intestinal segments (for CD) * Any condition that, in the investigator's judgment, may compromise patient safety, data integrity, or ability to participate in the study | → | Inclusion Criteria: * Age ≥21 years at the time of enrollment * Confirmed diagnosis of ulcerative colitis (UC) or Crohn's disease (CD) * Eligible for treatment with biologic therapy for IBD, as per the IBD Clinical Care Pathway * No prior exposure to mirikizumab and no contraindications to mirikizumab * Ability to provide informed consent * Willingness to comply with study procedures and follow-up requirements Exclusion Criteria: * Prior exposure to IL-23p19 antagonists (e.g., mirikizumab, risankizumab, guselkumab) * Prior exposure to small molecule targeted therapies for IBD (e.g., JAK inhibitors or S1P receptor modulators) * Participation in an interventional clinical trial within 90 days prior to enrollment * History of extensive colorectal resection, including: * Total proctocolectomy (for UC), or * Surgical removal of two or more intestinal segments (for CD) * Any condition that, in the investigator's judgment, may compromise patient safety, data integrity, or ability to participate in the study |
Not scored.No materiality record exists yet for this event.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.